

17 **Abstract**

18 We estimated the case-fatality rate (CFR) and ratios (RR) in adult COVID-19 cases with
19 hypertension and diabetes mellitus in the New York State. We found that the elderly population
20 had a higher CFR, but the elevated CFR ratios associated with comorbidities are more
21 pronounced for the younger population.

22

23 **Main text**

24 As of May 18, coronavirus disease 2019 (COVID-19) has affected more than 200 countries and
25 regions¹. The New York state was heavily impacted by the coronavirus with more than 22
26 thousands of deaths². Prior studies suggest that pre-existing health conditions such as
27 hypertension (HBP) and diabetes mellitus (DM) may exacerbate the severity of COVID-19³.
28 Quantitative assessments of the risk of death associated with them can inform the disease control
29 globally. However, few studies have estimated the corresponding case fatality rate for these two
30 comorbidities.

31

32 In this study, we aim to calculate the case-fatality rate (CFR) in adult COVID-19 cases with
33 hypertension and diabetes mellitus based on the publicly reported COVID-19 tracker data in the
34 New York State.

35

36 State-wide individual-level data of COVID-19 cases are not publicly available currently. In this
37 study, we aim to estimate CFR in COVID-19 patients with hypertension and diabetes mellitus
38 using aggregated level data from multiple sources. We first obtained the total number of
39 COVID-19 cases and deaths from public reports provided by the New York State Department of

40 Health². For each comorbidity, we then used the corresponding age-specific prevalence reported
41 from the Behavioral Risk Factor Surveillance System 2017 (BRFSS)⁴.

42
43 We defined the CFR of COVID-19 cases with one comorbidity as the total number of deaths
44 with the comorbidity divided by the total number of COVID-19 confirmed cases with that
45 comorbidity. To further control for age, we performed stratification and calculated the CFR by
46 different age groups (18-44 y, 45-64 y, and 65+ y).


47
48 We obtained the total number of COVID-19 deaths, deaths with comorbidities of hypertension
49 (D_{HBP}) or diabetes mellitus (D_{DM}), and the total number of confirmed cases from *the New York*
50 *State Department of Health COVID-19 Tracker*². The tracker, updated daily, includes counts of
51 confirmed cases from all lab testing samples, and age group-specific counts of deaths related to
52 comorbidities reported by health care facilities.

53
54 The counts of confirmed cases were reported without age group information in New York State,
55 so we estimated the age group-specific number of cases according to the age distribution of
56 confirmed COVID-19 cases in the contiguous US reported from the *Centers for Disease Control*
57 *and Prevention*⁵. In addition, information on comorbidities at an aggregate level was only
58 reported for deaths but not all confirmed cases from the Tracker. To estimate the number of
59 cases with hypertension (C_{HBP}) or diabetes mellitus (C_{DM}), we multiplied the counts of confirmed
60 cases by the corresponding prevalence of hypertension and diabetes mellitus in the New York
61 State from BRFSS⁴ 2017, assuming that the susceptibility of COVID-19 infection for patients of

62 these two comorbidities is similar to the general population. More details are provided in the
63 supplementary material.

64
65 Subsequently, we calculated the CFR for hypertension (CFR_{HBP}) or diabetes (CFR_{DM}) in each
66 age group. We further obtained the CFR ratio (RR) to compare the risk of COVID-19 death with
67 and without the comorbidities.

68
69 We restricted our analyses to COVID-19 deaths aged 18 years and above, which included
70 340,338 (96.9% of all cases) confirmed cases and 22,708 (99.9% of all deaths) deaths by the date
71 of May 18 in the New York State. Hypertension and diabetes mellitus in the New York State
72 were two common comorbidities of COVID-19 cases with the estimated prevalence of 32.2%
73 (95% CI: 30.4%, 34.0%) and 11.9% (95% CI: 10.6%, 13.2%), respectively. As expected, the
74 prevalence of hypertension (Figure 1A) and diabetes mellitus (Figure 1B) in COVID-19 cases
75 was highest among patients aged 65 years and above, with the case-fatality rate being 21.08%
76 (95% CI: 20.25%, 21.99%) for hypertension (Figure 1C) and 30.53% (95% CI: 28.11%, 33.40%)
77 for diabetes mellitus (Figure 1D). Compared with COVID-19 patients who were free of
78 hypertension, those with hypertension are associated with higher case-fatality rate ratios at 2.6
79 (95% CI: 2.3, 2.9), 1.7 (95% CI: 1.5, 1.8), and 1.0 (95% CI: 0.9, 1.1) for patients aged 18-44, 45-
80 64, and 65+ y, respectively. The corresponding case-fatality rate ratios for diabetes mellitus were
81 15.2 (95% CI: 12.2, 19.9), 4.1 (95% CI: 3.6, 4.6), and 1.7 (95% CI: 1.5, 1.9), respectively (Figure
82 1E).



84 **Figure 1** Estimation of the case-fatality rate in COVID-19 patients with hypertension or
85 diabetes. **A:** Age distribution of confirmed COVID-19 cases with hypertension. **B:** Age
86 distribution of confirmed COVID-19 cases with diabetes mellitus. **C:** Age group-specific case-
87 fatality rate among COVID-19 patients in all cases, with or without hypertension, respectively.
88 **D:** The COVID-19 age group-specific case-fatality rate in all cases, with or without diabetes,
89 respectively. **E:** The age group-specific case-fatality rate ratios (RR) of COVID-19 cases with
90 hypertension or diabetes.

91
92 We found that COVID-19 patients with hypertension and diabetes were associated with an
93 increased risk of death in New York State. While the elderly population had a higher CFR, the
94 elevated CFR ratios associated with comorbidities are more pronounced for the younger
95 population.

96
97 Our results should be considered as preliminary estimations with several limitations. The data
98 provided by the New York State Department of Health COVID-19 Tracker was at an aggregated
99 level with inconsistent stratifications of age. To calculate age group-specific results, we relied on
100 information from data sources of CDC and BRFSS to estimate age distribution and comorbidity
101 prevalence. Those estimations may be biased. In addition, with no individual-level data available
102 for the analyses, further investigations such as the interactions between comorbidities were not
103 conducted.

104 **Reference**

- 105 1. World Health Organization. Coronavirus disease (COVID-19) pandemic. Accessed May 20,
106 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- 107 2. New York State Department of Health. Novel Coronavirus (COVID-19). Accessed May 19,
108 2020. <https://coronavirus.health.ny.gov/>
- 109 3. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ*.
110 2020;368. doi:10.1136/bmj.m1198
- 111 4. Centers for Disease Control and Prevention. 2017 BRFSS Survey Data and Documentation.
112 Accessed May 31, 2020. https://www.cdc.gov/brfss/annual_data/annual_2017.html
- 113 5. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) in the
114 U.S. Accessed May 20, 2020. [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html)
115 [updates/cases-in-us.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html)

116

117 **About the Author**

118 Yang Ge is a Ph.D. candidate of Epidemiology and Biostatistics at the University of Georgia, Athens,
119 Georgia, USA. His areas of interest and research are infectious disease modeling and optimization of
120 vaccines.

121

122 **Address for correspondence:**

123 Yang Ge, Department of Epidemiology and Biostatistics, University of Georgia, 101 Buck Rd., Athens
124 30602-7396, Georgia, USA; email: yang.ge@uga.edu.

125 Shen Ye, Department of Epidemiology and Biostatistics, University of Georgia, 101 Buck Rd., Athens
126 30602-7396, Georgia, USA; email: yeshen@uga.edu.

127

128 **Conflict of Interest Disclosures:** No

129 **Funding/Support:** No

130 **Supplementary Material**

131 **Estimation of case-fatality rate in COVID-19 patients with hypertension and diabetes mellitus in**

132 **New York State**

133 Yang Ge, Shengzhi Sun, Ye Shen

134

135 **Table of Content**

136

137 **Table S1 Key data for case-fatality calculation**

Table S1 Key data for case-fatality calculation

Age Group	From the New York State Department of Health				From Behavioral Risk Factor Surveillance System (2017) *2	
	Confirmed cases*1	Total deaths	Death with hypertension (D _{HBP})	Death with diabetes (D _{DM})	Hypertension prevalence (%)	Diabetes prevalence (%)
18-44	135430	795	218	228	12.70 (11.38, 14.03)	2.58 (1.98, 3.18)
45-64	123600	4815	2399	1926	37.51 (35.58, 39.43)	14.04 (12.54, 15.54)
65+	81308	17098	9688	5972	56.52 (54.19, 58.85)	24.06 (21.99, 26.13)
Total	340338	22708	12305	8126		

139 *1: The age distribution of confirmed cases was estimated from the age distribution of confirmed cases in the contiguous US reported by the
 140 Centers for Disease Control and Prevention⁵.

141 *2: In the calculation of prevalence, pregnancy-related hypertension or diabetes mellitus were excluded.

142
 143 COVID-19 cases with hypertension (C_{HBP}) = Confirmed Cases × Hypertension prevalence

144 COVID-19 cases with diabetes (C_{DM}) = Confirmed Cases × Diabetes prevalence

145
 146 For each age group, we calculated the case-fatality rate and rate ratios with the following formulas:

147 $CFR_{HBP} = D_{HBP} / C_{HBP}$

148 $CFR_{Non-HBP} = (Total\ deaths - D_{HBP}) / (Confirmed\ Cases - C_{HBP})$

149 $RR_{HBP} = CFR_{HBP} / CFR_{Non-HBP}$

150 $CFR_{DM} = D_{DM} / C_{DM}$

151 $CFR_{Non-DM} = (Total\ deaths - D_{DM}) / (Confirmed\ Cases - C_{DM})$

152 $RR_{DM} = CFR_{DM} / CFR_{Non-DM}$

153
 154 Abbreviations:

155 CFR_{HBP}: case-fatality rate of COVID-19 with hypertension

156 CFR_{Non-HBP}: case-fatality rate of COVID-19 without hypertension

157 RR_{HBP}: case-fatality rate ratio of COVID-19 with hypertension

158 CFR_{DM}: COVID-19 case-fatality rate of COVID-19 with diabetes

159 CFR_{Non-DM}: case-fatality rate of COVID-19 without diabetes

160 RR_{DM}: case-fatality rate ratio of COVID-19 with diabetes